| Reference |
|---|
Liao R, Dewey M, Rong J, Johnson S, D Angelo W, Hussey G, et al. Matrix-bound nanovesicles alleviate particulate-induced periprosthetic osteolysis. Sci Adv. 2024;10:eadn1852 pubmed publisher |
Tang Y, Yang K, Liu Q, Ma Y, Zhu H, Tang K, et al. Preosteoclast plays a pathogenic role in syndesmophyte formation of ankylosing spondylitis through the secreted PDGFB - GRB2/ERK/RUNX2 pathway. Arthritis Res Ther. 2023;25:194 pubmed publisher |
Moreira M, de Ara xfa jo I, Fukada S, Venturini L, Guidorizzi N, Garrido C, et al. Refining Evaluation of Bone Mass and Adipose Distribution in Dunnigan Syndrome. Int J Mol Sci. 2023;24: pubmed publisher |
Pape J, Bakkalci D, Hosni R, Simpson B, Heikinheimo K, Fedele S, et al. RANKL neutralisation prevents osteoclast activation in a human in vitro ameloblastoma-bone model. J Tissue Eng. 2022;13:20417314221140500 pubmed publisher |
Ding D, Wang L, Yan J, Zhou Y, Feng G, Ma L, et al. Zoledronic acid generates a spatiotemporal effect to attenuate osteoarthritis by inhibiting potential Wnt5a-associated abnormal subchondral bone resorption. PLoS ONE. 2022;17:e0271485 pubmed publisher |
Guo H, Ding D, Wang L, Yan J, Ma L, Jin Q. Metformin attenuates osteoclast-mediated abnormal subchondral bone remodeling and alleviates osteoarthritis via AMPK/NF-κB/ERK signaling pathway. PLoS ONE. 2021;16:e0261127 pubmed publisher |
Xue J, Xu L, Zhu H, Bai M, Li X, Zhao Z, et al. CD14+CD16- monocytes are the main precursors of osteoclasts in rheumatoid arthritis via expressing Tyro3TK. Arthritis Res Ther. 2020;22:221 pubmed publisher |
Brunner J, Vulliard L, Hofmann M, Kieler M, Lercher A, Vogel A, et al. Environmental arginine controls multinuclear giant cell metabolism and formation. Nat Commun. 2020;11:431 pubmed publisher |
Lee K, Kim K, Kim B, Won J, Min H, Lee D, et al. Promotion of osteoclastogenesis by IL-26 in rheumatoid arthritis. Arthritis Res Ther. 2019;21:283 pubmed publisher |
Zoi I, Karamouzis M, Xingi E, Sarantis P, Thomaidou D, Lembessis P, et al. Combining RANK/RANKL and ERBB-2 targeting as a novel strategy in ERBB-2-positive breast carcinomas. Breast Cancer Res. 2019;21:132 pubmed publisher |
Li K, Chen S, Cai P, Chen K, Li L, Yang X, et al. MiRNA-483-5p is involved in the pathogenesis of osteoporosis by promoting osteoclast differentiation. Mol Cell Probes. 2020;49:101479 pubmed publisher |
Ogasawara N, Poposki J, Klingler A, Tan B, Hulse K, Stevens W, et al. Role of RANK-L as a potential inducer of ILC2-mediated type 2 inflammation in chronic rhinosinusitis with nasal polyps. Mucosal Immunol. 2020;13:86-95 pubmed publisher |
Yeh I, Chen S, Yen M, Wu Y, Hung C, Kuo P. 6-Shogaol Suppresses 2-Amino-1-Methyl-6-Phenylimidazo [4,5-b] Pyridine (PhIP)-Induced Human 786-O Renal Cell Carcinoma Osteoclastogenic Activity and Metastatic Potential. Nutrients. 2019;11: pubmed publisher |
Collins F, Stone M, Turton J, McCabe L, Wang E, Williams A. Oestrogen-deficiency induces bone loss by modulating CD14+ monocyte and CD4+ T cell DR3 expression and serum TL1A levels. BMC Musculoskelet Disord. 2019;20:326 pubmed publisher |
Löfvall H, Katri A, Dąbrowska A, Karsdal M, Luo Y, He Y, et al. GPDPLQ1237-A Type II Collagen Neo-Epitope Biomarker of Osteoclast- and Inflammation-Derived Cartilage Degradation in vitro. Sci Rep. 2019;9:3050 pubmed publisher |
Møller A, Füchtbauer E, Brüel A, Andersen T, Borggaard X, Pavlos N, et al. Septins are critical regulators of osteoclastic bone resorption. Sci Rep. 2018;8:13016 pubmed publisher |
Kjelgaard Petersen C, Platt A, Braddock M, Jenkins M, Musa K, Graham E, et al. Translational Biomarkers and Ex Vivo Models of Joint Tissues as a Tool for Drug Development in Rheumatoid Arthritis. Arthritis Rheumatol. 2018;70:1419-1428 pubmed publisher |
Davenport C, Harper E, Rochfort K, Forde H, Smith D, Cummins P. RANKL Inhibits the Production of Osteoprotegerin from Smooth Muscle Cells under Basal Conditions and following Exposure to Cyclic Strain. J Vasc Res. 2018;55:111-123 pubmed publisher |
Clarke A, Poulton L, Shim D, Mabon D, Butt D, Pollard M, et al. An anti-TL1A antibody for the treatment of asthma and inflammatory bowel disease. MAbs. 2018;10:664-677 pubmed publisher |
Hussein H, Boyaka P, Dulin J, Russell D, Smanik L, Azab M, et al. Cathepsin K Localizes to Equine Bone In Vivo and Inhibits Bone Marrow Stem and Progenitor Cells Differentiation In Vitro. J Stem Cells Regen Med. 2017;13:45-53 pubmed |
Sućur A, Jajic Z, Artuković M, Matijasevic M, Anic B, Flegar D, et al. Chemokine signals are crucial for enhanced homing and differentiation of circulating osteoclast progenitor cells. Arthritis Res Ther. 2017;19:142 pubmed publisher |
Lu B, Jiao Y, Wang Y, Dong J, Wei M, Cui B, et al. A FKBP5 mutation is associated with Paget's disease of bone and enhances osteoclastogenesis. Exp Mol Med. 2017;49:e336 pubmed publisher |
Chinetti Gbaguidi G, Daoudi M, Rosa M, Vinod M, Louvet L, Copin C, et al. Human Alternative Macrophages Populate Calcified Areas of Atherosclerotic Lesions and Display Impaired RANKL-Induced Osteoclastic Bone Resorption Activity. Circ Res. 2017;121:19-30 pubmed publisher |
Kamalakar A, Washam C, Akel N, Allen B, Williams D, Swain F, et al. PTHrP(12-48) Modulates the Bone Marrow Microenvironment and Suppresses Human Osteoclast Differentiation and Lifespan. J Bone Miner Res. 2017;32:1421-1431 pubmed publisher |
Bellini G, Torella M, Manzo I, Tortora C, Luongo L, Punzo F, et al. PKC?II-mediated cross-talk of TRPV1/CB2 modulates the glucocorticoid-induced osteoclast overactivity. Pharmacol Res. 2017;115:267-274 pubmed publisher |
Savage J, Pulsipher A, Rao N, Kennedy T, Prestwich G, Ryan M, et al. A Modified Glycosaminoglycan, GM-0111, Inhibits Molecular Signaling Involved in Periodontitis. PLoS ONE. 2016;11:e0157310 pubmed publisher |
Wang X, Wei W, Krzeszinski J, Wang Y, Wan Y. A Liver-Bone Endocrine Relay by IGFBP1 Promotes Osteoclastogenesis and Mediates FGF21-Induced Bone Resorption. Cell Metab. 2015;22:811-24 pubmed publisher |
Kasonga A, Deepak V, Kruger M, Coetzee M. Arachidonic acid and docosahexaenoic acid suppress osteoclast formation and activity in human CD14+ monocytes, in vitro. PLoS ONE. 2015;10:e0125145 pubmed publisher |
Zhu K, Yi J, Xiao Y, Lai Y, Song P, Zheng W, et al. Impaired bone homeostasis in amyotrophic lateral sclerosis mice with muscle atrophy. J Biol Chem. 2015;290:8081-94 pubmed publisher |
Alshbool F, Mohan S. Differential expression of claudin family members during osteoblast and osteoclast differentiation: Cldn-1 is a novel positive regulator of osteoblastogenesis. PLoS ONE. 2014;9:e114357 pubmed publisher |
Kalbasi Anaraki P, Patecki M, Tkachuk S, Kiyan Y, Haller H, Dumler I. Urokinase receptor mediates osteoclastogenesis via M-CSF release from osteoblasts and the c-Fms/PI3K/Akt/NF-κB pathway in osteoclasts. J Bone Miner Res. 2015;30:379-88 pubmed publisher |
Zheng Y, Chow S, Boernert K, Basel D, Mikuscheva A, Kim S, et al. Direct crosstalk between cancer and osteoblast lineage cells fuels metastatic growth in bone via auto-amplification of IL-6 and RANKL signaling pathways. J Bone Miner Res. 2014;29:1938-49 pubmed publisher |
Yeon J, Kim K, Choi S, Moon S, Park Y, Ryu B, et al. Anti-osteoclastogenic activity of praeruptorin A via inhibition of p38/Akt-c-Fos-NFATc1 signaling and PLC?-independent Ca2+ oscillation. PLoS ONE. 2014;9:e88974 pubmed publisher |
Liu Z, Xu J, Li H, Zheng Y, He J, Liu H, et al. Bone marrow stromal cells derived MCP-1 reverses the inhibitory effects of multiple myeloma cells on osteoclastogenesis by upregulating the RANK expression. PLoS ONE. 2013;8:e82453 pubmed publisher |
Chen C, Cheng P, Xie H, Zhou H, Wu X, Liao E, et al. MiR-503 regulates osteoclastogenesis via targeting RANK. J Bone Miner Res. 2014;29:338-47 pubmed publisher |
He W, Mazumder A, Wilder T, Cronstein B. Adenosine regulates bone metabolism via A1, A2A, and A2B receptors in bone marrow cells from normal humans and patients with multiple myeloma. FASEB J. 2013;27:3446-54 pubmed publisher |
Wilson T, Fridlyand J, Yan Y, Penuel E, Burton L, Chan E, et al. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature. 2012;487:505-9 pubmed publisher |
Søe K, Delaisse J. Glucocorticoids maintain human osteoclasts in the active mode of their resorption cycle. J Bone Miner Res. 2010;25:2184-92 pubmed publisher |
Boissy P, Andersen T, Lund T, Kupisiewicz K, Plesner T, Delaisse J. Pulse treatment with the proteasome inhibitor bortezomib inhibits osteoclast resorptive activity in clinically relevant conditions. Leuk Res. 2008;32:1661-8 pubmed publisher |
Colucci S, Brunetti G, Cantatore F, Oranger A, Mori G, Quarta L, et al. Lymphocytes and synovial fluid fibroblasts support osteoclastogenesis through RANKL, TNFalpha, and IL-7 in an in vitro model derived from human psoriatic arthritis. J Pathol. 2007;212:47-55 pubmed |
Tang C, Hsu T, Lin W, Lai M, Yang R, Hsieh S, et al. Attenuation of bone mass and increase of osteoclast formation in decoy receptor 3 transgenic mice. J Biol Chem. 2007;282:2346-54 pubmed |
Kawai T, Matsuyama T, Hosokawa Y, Makihira S, Seki M, Karimbux N, et al. B and T lymphocytes are the primary sources of RANKL in the bone resorptive lesion of periodontal disease. Am J Pathol. 2006;169:987-98 pubmed |
Grimaud E, Soubigou L, Couillaud S, Coipeau P, Moreau A, Passuti N, et al. Receptor activator of nuclear factor kappaB ligand (RANKL)/osteoprotegerin (OPG) ratio is increased in severe osteolysis. Am J Pathol. 2003;163:2021-31 pubmed |
